Shares of Versartis Inc. (NASDAQ:VSAR) were down 3.3% during trading on Thursday . The stock traded as low as $9.85 and last traded at $9.98, with a volume of 58,640 shares trading hands. The stock had previously closed at $10.32.

Several analysts recently commented on VSAR shares. Canaccord Genuity reiterated a “buy” rating on shares of Versartis in a research note on Monday, April 4th. Northland Securities started coverage on shares of Versartis in a research note on Thursday, April 7th. They issued an “outperform” rating for the company. Zacks Investment Research upgraded shares of Versartis from a “sell” rating to a “hold” rating in a research note on Tuesday, May 31st. Finally, Morgan Stanley reiterated a “hold” rating on shares of Versartis in a research note on Saturday, April 30th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. Versartis currently has a consensus rating of “Hold” and an average price target of $17.20.

The firm’s market capitalization is $311.94 million. The stock has a 50-day moving average price of $10.33 and a 200 day moving average price of $9.38.

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing long-acting recombinant human growth hormone (rhGH), somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s product pipeline includes VRS-317 and XTEN Technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.